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Abstract
Antipsychotic medications are clearly identified as important in the treatment of individuals with schizophrenia and with
bipolar disorder. However, negative societal reaction related to having a serious mental illness and the socially undesirable
side effects associated with antipsychotic medication treatment may combine to worsen stigma associated with treatment for
mental illness. Specific stigmatizing effects of antipsychotic therapy may be difficult to evaluate independently from factors
such as symptoms, insight into illness and side effects. Attitudes towards antipsychotic medication may be positive in
individuals who recognize therapeutic drug effects, however other individuals may view medications negatively due to a sense
of stigma. Stigma among individuals with bipolar disorder in relation to treatment with antipsychotic medication has not
been well addressed in the literature. An additional concern among individuals with bipolar disorder who receive
antipsychotic medications may be the notion that antipsychotics are ‘schizophrenia drugs’, and thus an inappropriate
treatment for their condition. Antipsychotic medications can be stigmatizing for patients with serious mental illness, however
the roots of stigma are extensive, and efforts to minimize stigma can only be successful when addressed by the individual with
illness, their families and loved ones, treatment providers and society at large.
Antipsychotic medications and the
treatment of serious mental illness
Antipsychotic medications are a cornerstone of
treatment for individuals with serious mental illness,
and have been widely utilized since the introduction
of chlorpromazine five decades ago. For the treat-
ment of patients with schizophrenia, the conven-
tional antipsychotic agents as a class ushered in the
era of modern psychopharmacology. Conventional
antipsychotic medications are effective in reducing
psychotic symptoms, but differ in their potency and
side effect profiles. A major concern with conven-
tional antipsychotic medications is their propensity to
induce extrapyramidal symptoms and tardive dyski-
nesia (TD), a condition that is potentially debilitating
and often creates social problems for affected
individuals due to obvious, involuntary movements
of the face, neck, trunk or extremities (Katschnig,
2000; Simpson, Pi, & Sramek, 1982). Individuals
with severe TD may be ostracized because their
appearance and psychosocial difficulties are common
in individuals with severe forms of TD (Yassa, 1989).
Since the 1990s when clozapine and other novel or
atypical antipsychotic drugs were introduced, the use
of antipsychotic medications has become more
complex. Compared to older agents, atypical anti-
psychotic agents have a reduced propensity to cause
extrapyramidal symptoms, but may be associated
with other side effects that create socially undesirable
conditions such as weight gain and obesity
(American Diabetes Association & American
Psychiatric Association, 2004). A recent report
comparing medication treatment outcomes among
1493 patients with schizophrenia (Lieberman et al.,
2005), the US CATIE (Clinical Antipsychotic Trials
of Intervention Effectiveness) study, suggested that
over an 18-month period, approximately 74% of
patients with schizophrenia discontinued antipsy-
chotic medication. The majority of individuals
prescribed antipsychotic drugs, which included
both newer atypical agents as well as the conven-
tional neuroleptic perphenazine, stopped assigned
treatment owing to inefficacy, intolerable side effects
or for other reasons (Lieberman et al., 2005). It is
notable that nearly 30% of individuals in treatment in
the CATIE study stopped medication on their own.
Thus, while newer drugs may have differing side
effect profiles compared to older agents, it appears
as though acceptability of antipsychotic agents from a
patient perspective is still quite limited.
Over the last decade, antipsychotic agents,
particularly the newer, atypical antipsychotic
compounds have been widely used to treat patients
with bipolar disorder, and in fact there has
been a convergence of treatment modalities
for schizophrenia and for bipolar disorder
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(Citrome, Goldberg, & Stahl, 2005). Data from a
large, US government healthcare database in 2003
suggested that 45% of individuals with bipolar
disorder are prescribed antipsychotic medications,
usually on a long-term basis (Sajatovic, Valenstein,
Blow, Ganoczy, & Ignacio, 2006). Side effects with
antipsychotic medication treatment among individ-
uals with bipolar disorder may be substantial, and it
has been reported that some side effects, such
as weight gain, may be compounded when
antipsychotic drugs are used concomitantly with
traditional mood stabilizing medication such as
lithium or anticonvulsant medications (Ghaemi,
2000). It has been demonstrated that approximately
one in two individuals with bipolar disorder do not
take antipsychotic medications as prescribed
(Sajatovic et al., 2006).
Thus, antipsychotic compounds are widely
prescribed to treat individuals with serious mental
illness, including patients with schizophrenia,
schizoaffective disorder and bipolar disorder.
Unfortunately, in spite of substantial technological
gains there appear to be significant obstacles to best
outcomes including non-adherence with treatment.
Stigma and antipsychotic medications
While antipsychotic medications are clearly identi-
fied as treatments of choice in the management of
both schizophrenia and of bipolar disorder
(American Psychiatric Association, 2002; Gaebel,
Weinmann, Sartorius, Rutz, & McIntyre, 2005)
many individuals with these disorders, as noted
above, do not take prescribed medications. It is
likely that stigma related to having a serious mental
illness and the socially undesirable side effects
associated with antipsychotic medication treatment
may combine to worsen stigma associated with
treatment for mental illness, and in more extreme
cases, may contribute to treatment non-adherence.
Lee, Chiu, Tsang, Chui, and Kleinman (2006)
recently evaluated the issue of stigma among
Chinese patients with schizophrenia via use of focus
groups and a questionnaire administered to 320
patients with schizophrenia and 160 patients with
diabetes. Results suggested that patients with schizo-
phrenia were more stigmatized than patients with
diabetes, and that medication-induced stigma
occurred in 48% of individuals with schizophrenia.
Stigma led to unwelcome disclosure of illness,
workplace difficulties, family rejection and treatment
non-adherence. Hudson and colleagues (2004)
analysed barriers to medication adherence among
153 patients with schizophrenia, and found that the
most common patient-reported barriers included
stigma of taking medications and of adverse drug
reactions (forgetfulness and lack of social support
were also noted to be significant barriers to
medication adherence).
Numerous reports dealing with the individual and
larger effects of stigma suggest that stigma is
problematic on multiple levels, affecting not only
the individual with serious mental illness, but also
has negative effect on families and caregivers (Rudge
& Morse, 2004; Struening et al., 2001; Tsang, Tam,
Chan, & Cheung, 2003). Struening (2001)
conducted a study of 461 caregivers of persons
with serious mental illness to evaluate caregiver’s
perceptions of the extent of society’s devaluation of
consumers and their families. Most (70%) caregivers
indicated a belief that patients with serious mental
illness are devalued, and 43% expressed the belief
that patient families are devalued as well (Struening
et al., 2001). There was no difference in perception
of devaluation between families of patients with
schizophrenia vs. patients with bipolar disorder.
Subjective experience of taking antipsychotic
medications among populations with serious
mental illness
Subjective experience of illness refers to the psycho-
cultural perception of illness lived by an individual.
Subjective experience may vary in relation to
ethnicity, age, gender, and socioeconomic status,
and is a dynamic process that is likely to change over
an individual’s life time and circumstances.
Subjective experience with respect to antipsychotic
medications among individuals with serious
mental illness appears to be highly variable
(Carrick, Mitchell, Powell, & Lloyd, 2004;
Davidhizar, 1985; Jenkins et al., 2005). Among
some individuals, severe negative emotional/physical
response in relation to conventional antipsychotic
treatment – ‘dysphoria’ – may lead to non-adherence
with treatment, poor outcomes or even suicidal
behaviour (Awad, Voruganti, Keslegrave, & Hogan,
1996; Moore, Sellwood, & Stirling, 2000; Van
Putten, May, Marder, & Wittmann, 1981). At the
other end of the spectrum, individuals receiving
antipsychotic medications may perceive a daily
benefit from taking their medication ( Jenkins et al.,
2005; Loffler, Kilian, Toumi, & Angermeyer, 2003).
Despite substantial side effects from medication
such as weight gain, some individuals perceive an
advantage to medication treatment with respect to
reduced relapse rates and fewer hospitalizations
(Jenkins et al., 2005). Other individuals may perceive
both positive and negative aspects of antipsychotic
medication treatments (Loffler et al., 2003), but may
not always be able to readily articulate their varied
components of subjective response to medication
(Carrick et al., 2004).
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Carrick and colleagues (2004) conducted a
qualitative evaluation of subjective experience of
side effects of antipsychotic medication using both
in-depth interview analysed using grounded theory,
and then a subsequent series of focus groups. Results
indicated that individuals on antipsychotics did not
see side effects and symptoms as separate issues, but
described drugs as ‘good’ or ‘terrible’, an indication
of the total impact of their treatment. Some patients
with schizophrenia in the study by Carrick and
colleagues (2004) expressed the notion that the
‘medical establishment’ wanted to keep people on
medication, sometimes seen by patients as unsuitable
or at higher levels than the patient wished.
Against this rather complicated contextual
background where subjective experience is a combi-
nation of patient factors, the treatment relationship
and the cultural/social setting, specific stigmatizing
effects of antipsychotic therapy may be somewhat
difficult to evaluate independently from factors such
as symptoms, insight into illness, and side effects.
Loffler and colleagues (2003) evaluated 307
schizophrenic patient’s subjective reasons for
compliance and non-compliance with neuroleptic
treatment using a standardized rating scale, the
Rating of Medication Influences (ROMI), developed
by Weiden (1994). While approximately half of
patients in the study by Loffler considered adverse
effects to be a reason for medication non-adherence,
the authors also noted ‘Nearly every tenth patient
was reluctant to take the medication because of
embarrassment over the illness or the treatment, or
because he or she was afraid to experience any kind
of stigmatization because of the treatment’ (Loffler
et al., 2003). In the report by Loffler et al. (2003)
embarrassment or stigma over medication or illness
did not significantly differ between conventional oral
neuroleptic medications, atypical antipsychotic
medications, depot neuroleptics or combined neu-
roleptic medications. However, men were less likely
to refuse drug treatment because of stigmatization
compared to women (OR¼ 0.353, p¼ 0.028).
Freudenreich and colleagues (2004) conducted a
cross-sectional study of 81 outpatients with schizo-
phrenia to evaluated clinical and demographic
predictors of drug attitude, as measured by a
standardized instrument, the Drug Attitude
Inventory (Awad et al., 1993). Freudenreich and
colleagues (2004) demonstrated that less awareness
of current symptoms, presence of deficit symptoms
and employment predicted a negative attitude
towards medications, while extrapyramidal symp-
toms did not predict attitude and there was no
difference between first- or second-generation
antipsychotics. The authors concluded that while
attitudes may be more positive in patients who
recognize therapeutic drug effects, patients who
work may view medications particularly negatively,
possibly due to a sense of stigma (Freudenreich,
Cather, Evins, Henderson, & Goff, 2004).
Populations with schizophrenia
Jenkins and colleagues (2005) recently conducted a
study to evaluate subjective experience of treatment
with antipsychotic medications. The project, funded
by NIMH (MH-60232) was entitled the ‘Subjective
Experience and the Culture of Recovery with
Atypical Antipsychotics (SEACORA)’ study, and
involved 90 community out-patient subjects with
schizophrenia or schizo-affective disorder (according
to SCID research diagnostic criteria). The research
participants were studied in relation to
their subjective experience of the atypical or
second-generation antipsychotic medication they
were taking (Table I). Data were derived primarily
from semi-structured anthropological interviews
(Subjective Experience of Medication Interview
of SEMI) that inquired into everyday routines,
medication and treatment, and the experience of
stigma (Jenkins & Carpenter-Song, 2005).
Coding was completed by the authors (JHJ, ECS)
having established coding definitions. Inter-rater
reliability of coding at the most basic levels of
analysis was completed by independent co-ratings
of twenty randomly chosen cases that were tallied
and analysed for kappa co-efficients of agreement
Table I. Sociodemographic and clinical characteristics seacora
participants (n¼90).
Gender
Male 49 54.4
Female 41 45.5
Ethnicity
Euro-American 70 77.8
African American 20 22.2
Mean Age (SD) 40.7 (7.9)
Diagnosis
Schizophrenia 73 81.1
Schizo-affective 17 18.9
Mean age at onset (SD) 20.6 (7.3)
Mean years ill (SD) 20.1 (8.4)
Hospital Admissions
Mean (SD) 7.0 (7.0)
Current atypical antipsychotic
Clozapine 51 56.7
Risperidone 16 17.8
Olanzapine 15 16.7
Other 8 8.9
Note: *Due to rounding, percent may not equal 100; Adapted
from: Jenkins, J. H., Strauss, M. E., Carpente, E. A., Miller, D.,
Floersch, J., & Sajatovic, M. Subjective experience of recovery
from schizophrenia-related disorders and atypical antipsychotics.
International Journal of Social Psychiatry, 51, 211–217.
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by the project co-investigator (Milton Strauss) with
substantial psychological research design and
statistical expertise.
A subject’s narrative experience was coded for the
presence of stigma if at least one of the following
conditions were met: (1) the subject conveyed that
social response was negative with respect to how
others respond to his/her illness; (2) the subject
indicated they perceived stigma in relation to their
illness; (3) the subject articulated that s/he does not
tell others that s/he has a mental illness or that s/he
takes medication. In situations where the subject
expressed no attempt to conceal illness or medication
from others, or in which the subject did not elaborate
on stigma, the absence of stigma was coded. Coding
a ‘no’ response cannot be considered an indication
that the subject did not perceive or experience stigma
but rather that the response reflects an absence of a
narrative report of stigma in the interview transcript.
Good inter-rater reliability (Kappa¼ 0.64) was
obtained for the coding schema. One pair of raters
independently coded 20 randomly selected
responses. We found that the subjective experience
of stigma was pervasive, occurring across an
array of social settings, with 96% reporting awareness
of stigma according to responses coded reliably
in relation to operational criteria (Jenkins &
Carpenter-Song, 2005). In addition, we identified
nine primary contexts for the awareness of stigma
and mental illness of which subjects were aware:
(1) gender; (2) work; (3) social relations (family,
friends, acquaintances); (4) dating; (5) medications;
(6) self-presentation; (7) popular and media
perceptions; (8) reproduction of stigma; and (9)
social class and ethnicity ( Jenkins & Carpenter-
Song, 2005). An example of a Euro-American male
who struggled with stigma attached to medication is
taken from the following qualitative SEMI excerpt:
I’ll tell people I’m taking an antipsychotic, and
they’re like ‘You don’t need to take that.’ They
just give you that look, that shocked look, and
then that jump a couple steps back. And I say,
‘I know I have to take it, because I’ve been
without it before’. . . And they start arguing
with me, and I just leave and look back,
because I know better.
Populations with bipolar disorder
Stigma among individuals with bipolar disorder has
not been widely studied (Hayward, Wong, Bright, &
Lam, 2002), and the specific point of subjective
experience and of stigma in relation to treatment
with antipsychotic medication has not been well
addressed in the literature. Hayward and colleagues
(2002) suggested that the issue of stigmatization is
of considerable clinical significance among individ-
uals with bipolar disorder, and appears to be
relatively independent of mood state. A recent
report by Sajatovic and Jenkins (2006) noted that
stigma is widely experienced by patients with bipolar
disorder, and does not appear to differ greatly among
men or women or be experienced differently by
individuals of different ages. Individuals with bipolar
disorder may have had prior negative subjective
experience with antipsychotic agents that may affect
their future outlook on antipsychotic therapy, and
which, when combined with the stigmatizing effects
of medication treatment in general, may put
these individuals at particularly high risk for non-
adherence and poor outcome. Strejilevich and Garcia
Bonetto (2003) identified the neuroleptic drug
haloperidol as the compound to which the largest
proportion of patients with bipolar disorder (86%)
rated as their ‘worst’ treatment memory. In contrast,
in the report by Strejilevich and Garcia Bonetto
(2003), drugs related to ‘best’ treatment memories
by patients with bipolar disorder were lithium and
divalproex. It is not clear how newer antipsychotic
drugs may be subjectively experienced by patients
with bipolar disorder compared to older neuroleptic
agents.
An additional concern among individuals
with bipolar disorder who receive antipsychotic
medications may be the notion that antipsychotics
are ‘schizophrenia drugs’, and thus an inappropriate
treatment for their condition. Highet and Colleagues
(2004) conducted a qualitative analysis of treatment
experience for individuals with bipolar disorder that
included 49 people participating in focus groups or
in-depth interviews. A major concern expressed by
patients with bipolar disorder was delayed or
inaccurate diagnosis of bipolar disorder, a situation
that persisted for many years for some patients.
Individuals were most often diagnosed incorrectly as
having schizoaffective disorder, attention deficit
hyperactivity disorder, unipolar depression and/or
psychosis (Highet, McNair, Thompson, Davenport,
& Hickie 2004). One might expect that unless the use
of antipsychotic medication is clearly explained as an
appropriate treatment for bipolar illness among
individuals who have previously been incorrectly
diagnosed, it is possible that use of antipsychotic
drugs may be perceived as stigmatizing and consis-
tent with an inaccurate diagnosis.
Minimizing stigma associated with
antipsychotic therapy in patients with
serious mental illness
It is clear that antipsychotic medications can be
stigmatizing for patients with serious mental illness,
however the roots of stigma are extensive, and efforts
110 M. Sajatovic & J. H. Jenkins
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to minimize stigma can only be successful when
addressed by the individual with an illness, their
families and loved ones, treatment providers and
society at large. On an individual level, education
regarding the biological constructs of illness, and
involvement in self-help or peer support groups may
be beneficial in combating the malignant effects of
stigma on self-esteem. While membership in a
stigmatized group is often assumed to have negative
consequences (Camp, Finlay, & Lyons, 2002),
individuals with serious mental illness may find
ways of coping with stigma that are positive and
constructive, thus delineating a clear difference
between society’s negative representations of the
mentally ill and their own personal, ‘no-fault’
construction of illness. Camp and colleagues
(2002) have noted that among women with chronic
mental illness, personal rejection of critical and
stigmatizing labels has a protective effect on
self-esteem. Families and significant others also
may benefit from education regarding illness and
consumer organizations that may lessen family
burden and stigmatization. It has been noted that
distress to family members and caregivers is further
compounded by lack of information, and exclusion
from the treatment and management process (Highet
et al., 2004). Providers can minimize the stigmatizing
effects of antipsychotic medication by particular
attentiveness to adverse effects that patients may be
reluctant to admit cause social embarrassment or
distress such as weight gain or sexual dysfunction.
Treatment regimens that do not expose the mentally
ill individual to possible negative attention such as
having to take medication at work or school should
be avoided if at all possible. Finally, the mental
health community is obligated to address the issue of
stigma in all its variations – not just with respect to
having an illness, but all the effort and commitment
that treatment and recovery entail.
Conclusion
Treatment with antipsychotic medications may
contribute to stigma experienced by individuals
with serious mental illnesses such as schizophrenia,
schizoaffective disorder or bipolar disorder. While
newer antipsychotic drugs may have fewer or
different side effects compared to older neuroleptic
agents, stigma may remain a substantial influence on
medication adherence. In fact, on the basis of
research in schizophrenia (Jenkins & Carpenter-
Song, 2005; Jenkins et al., 2005; Lee, 2006;
Stuening, 2001), and in bipolar disorder (Hayward
et al., 2002; Sajatovic et al., 2006) it appears that
stigma associated with antipsychotic medications is
not only pernicious, but pervasive across an array of
personal and social contexts. Efforts to minimize
stigma must include patients, families, providers and
society at large.
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